ArticleCell reports methods2026
Off-target effects of DREADD ligands revealed by an anesthesia emergence paradigm in mice.
Article in Cell reports methods, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Designer receptors exclusively activated by designer drugs (DREADDs) enable reversible control of specific neural circuits, but the pharmacological neutrality of their ligands is increasingly questioned. Here, we introduce an anesthesia emergence paradigm to systematically assess the off-target effects of DREADD ligands in DREADD-naive mice. We show that intraperitoneal administration of clozapine N-oxide (CNO), compound 21 (C21), or deschloroclozapine (DCZ) delays motor recovery from isoflurane anesthesia. CNO produced the largest delay, likely due to its back-conversion to clozapine. DCZ showed the smallest effect magnitude, although its difference from C21 remained inconclusive. We then show that subcutaneous administration, which should reduce clozapine back-conversion, reduces the CNO-induced recovery delay to levels comparable to those of C21. Finally, we provide a freely available, deep-learning-based automated behavioral pipeline that integrates the anesthesia emergence paradigm with a reproducible analysis tool for future studies. Together, these results underscore the importance of accounting for ligand off-target effects through careful dose selection and DREADD-free, ligand-treated controls in chemogenetic experiments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.